Claudia Ferrara

Roche (Switzerland) — Switzerland

Medicine · Health Sciences

23h-index4.3kcitations104works0.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(42), CAR-T cell therapy research(25), Peptidase Inhibition and Analysis(20), Cardiomyopathy and Myosin Studies(16), Glycosylation and Glycoproteins Research(13)

Publications104 total

Vascularized tumor organoids enable immunotherapy testing in tumor-remodeled stroma
2026Open Access
P329G-engager: a universal mix & match antibody-based adaptor platform for cancer immunotherapy
mAbs·2025Open Access
CEA-4-1BBL: CEACAM5-Targeted 4-1BB Ligand Fusion Proteins for Cis Co-Stimulation with CEA-TCB
Antibodies·2025Open Access
CEA-4-1BBL: CEACAM5-Targeted 4-1BB Ligand Fusion Proteins for Cis Co-Stimulation with CEA-TCB
Preprints.org·2025Open Access
Co-expression of an adapter CAR retains efficacy of CAR T cells after single and dual antigen loss in lymphoma
Molecular Therapy·2025· 1 citedOpen Access
CEA-4-1BBL: Design and Optimization of a Novel CEACAM5-Targeted 4-1BB Ligand Antibody Fusion Protein to Provide Costimulation in Cis in Combination with T Cell Bispecific Antibodies
Preprints.org·2025Open Access
Rehabilitation intervention to prevent adverse events related to ADT in patients with metastatic prostate cancer
Future Science OA·2025Open Access
2503P Rehabilitation intervention to prevent adverse events (AE) related to androgen-deprivation therapy (ADT) in metastatic prostate cancer (mPCa) patients: A feasibility study (ReCaP)
Annals of Oncology·2025
Abstract A054: Recruiting innate immune cells universally: Development of a novel universal innate cell engager for cancer-immunotherapy
Cancer Immunology Research·2024
Abstract 6709: P329G-Engager: A novel universal antibody-based adaptor platform for cancer immunotherapy
Cancer Research·2024
Supplementary Figure S2 and Table S4 from RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis
2023Open Access
Supplementary Figure S2 and Table S4 from RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis
2023Open Access
Supplementary Figure S3 from RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis
2023Open Access
Data from RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis
2023Open Access
Supplementary Figure S3 from RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis
2023Open Access
Supplementary Figure S1, Table S1, and Table S2 from RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis
2023Open Access
Supplementary Figure S4 from RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis
2023Open Access
Supplementary Figure S4 from RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis
2023Open Access
Supplementary Methods from RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis
2023Open Access
Supplementary Table S3 from RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Pablo Umaña(25), Christian Klein(23), Peter Brünker(14), Marina Bacac(13), Christina Claus(12), Johannes Sam(10), Sylvia Herter(9), Corrado Poggesi(9), Ekkehard Mössner(8), Valeria Nicolini(8), Maria Amann(8), Beatrice Scellini(8), Nicoletta Piroddi(8), Chiara Tesi(8), Sandra Grau-Richards(5), Frank Herting(5), Christoph M. Griessinger(5), Tove Olafsen(5), Alessandro Mascioni(5), Ziyue Karen Jiang(5)